Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor
Processed 2,841 EsoGuard ® tests and recognized 3Q25 revenue of $1.2 million, ending quarter with over $47 million in proforma cash and extending runway through 2026 and well past upcoming reimbursement...
Conference Call and Webcast at 8:30 AM Eastern Time
NEW YORK , Oct. 15, 2025 /PRNewswire/ --Â Lucid Diagnostics Inc. Â (Nasdaq: LUCD) Â ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and...
Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors
Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion...
NEW YORK , Sept. 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. Â (Nasdaq: LUCD)Â ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company,...
NEW YORK , Sept. 10, 2025 /PRNewswire/ --Â Lucid Diagnostics Inc. Â (Nasdaq: LUCD)Â ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company,...
NEW YORK , Sept. 9, 2025 /PRNewswire/ --Â Lucid Diagnostics Inc. Â (Nasdaq: LUCD)Â ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company,...
Conference call scheduled for Monday, September 8 , at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting